868P Phase II trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
Saved in:
| Title: | 868P Phase II trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). |
|---|---|
| Authors: | Wong, W.1 (AUTHOR), Adkins, D.R.2 (AUTHOR), Misleh, J.G.3 (AUTHOR), Lorch, J.4 (AUTHOR), Grewal, J.S.5 (AUTHOR), Russell, J.6 (AUTHOR), Cetnar, J.7 (AUTHOR), Ho, A.L.1 (AUTHOR), Chen, K.8 (AUTHOR), Aysola, K.8 (AUTHOR), Thomas, J.9 (AUTHOR) |
| Source: | Annals of Oncology. 2024 Supplement 2, Vol. 35, pS622-S623. 2p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
